54.99
Schlusskurs vom Vortag:
$55.22
Offen:
$54.79
24-Stunden-Volumen:
679.43K
Relative Volume:
0.78
Marktkapitalisierung:
$3.41B
Einnahmen:
$45.48M
Nettoeinkommen (Verlust:
$169.95M
KGV:
20.99
EPS:
2.62
Netto-Cashflow:
$230.85M
1W Leistung:
-0.60%
1M Leistung:
+3.09%
6M Leistung:
+49.11%
1J Leistung:
+52.33%
Protagonist Therapeutics Inc Stock (PTGX) Company Profile
Firmenname
Protagonist Therapeutics Inc
Sektor
Branche
Telefon
(510) 474-0170
Adresse
7707 GATEWAY BLVD., SUITE 140, NEWARK, CA
Vergleichen Sie PTGX mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
PTGX
Protagonist Therapeutics Inc
|
54.99 | 3.43B | 45.48M | 169.95M | 230.85M | 2.62 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-06-17 | Eingeleitet | Citigroup | Buy |
2024-12-06 | Eingeleitet | BMO Capital Markets | Outperform |
2024-12-06 | Eingeleitet | Goldman | Neutral |
2024-11-05 | Eingeleitet | Wedbush | Outperform |
2024-09-24 | Eingeleitet | TD Cowen | Buy |
2024-09-09 | Eingeleitet | Truist | Buy |
2023-10-30 | Eingeleitet | CapitalOne | Overweight |
2023-05-25 | Fortgesetzt | Jefferies | Buy |
2022-08-25 | Eingeleitet | JMP Securities | Mkt Outperform |
2022-02-11 | Eingeleitet | BTIG Research | Buy |
2021-10-12 | Hochstufung | JP Morgan | Neutral → Overweight |
2021-10-11 | Hochstufung | Northland Capital | Market Perform → Outperform |
2021-09-20 | Herabstufung | JP Morgan | Overweight → Neutral |
2021-05-24 | Eingeleitet | JMP Securities | Mkt Outperform |
2021-05-24 | Eingeleitet | Northland Capital | Outperform |
2021-01-06 | Eingeleitet | JP Morgan | Overweight |
2020-12-16 | Eingeleitet | Piper Sandler | Overweight |
2020-09-18 | Bestätigt | H.C. Wainwright | Buy |
2020-07-15 | Eingeleitet | Jefferies | Buy |
2020-05-18 | Bestätigt | H.C. Wainwright | Buy |
2019-07-08 | Eingeleitet | H.C. Wainwright | Buy |
2019-05-09 | Hochstufung | Stifel | Hold → Buy |
2018-12-06 | Eingeleitet | Nomura | Buy |
2018-01-29 | Eingeleitet | Stifel | Buy |
2017-07-21 | Eingeleitet | BTIG Research | Buy |
Alle ansehen
Protagonist Therapeutics Inc Aktie (PTGX) Neueste Nachrichten
Protagonist Therapeutics Inc. Stock Analysis and ForecastRapid-fire capital growth - jammulinksnews.com
What drives Protagonist Therapeutics Inc. stock priceExplosive wealth accumulation - jammulinksnews.com
What analysts say about Protagonist Therapeutics Inc. stockConsistent triple returns - jammulinksnews.com
Is Protagonist Therapeutics Inc. a good long term investmentBreakout stock performance - jammulinksnews.com
Protagonist Announces Submission of NDA for First Icotrokinra U.S. FDA Approval Aiming to Revolutionize Treatment Paradigm for Adults and Adolescents with Plaque Psoriasis - Lubbock Avalanche-Journal
Polycythemia Vera Pipeline 2025: Latest FDA Approvals, - openPR.com
Protagonist Therapeutics to Host Conference Call to Announce an Oral Obesity Development Candidate - Lancaster Eagle-Gazette
Protagonist Announces Submission of NDA for First Icotrokinra U. - GuruFocus
How the (PTGX) price action is used to our Advantage - news.stocktradersdaily.com
How Protagonist Therapeutics Inc. stock performs during market volatilityLow Risk Stock Strategies - Newser
Why Protagonist Therapeutics Inc. stock attracts strong analyst attentionFree Exclusive Investment Tips - Newser
What makes Protagonist Therapeutics Inc. stock price move sharplyReal Time Stock Signal - Newser
Insiders At Protagonist Therapeutics Sold US$5.1m In Stock, Alluding To Potential Weakness - 富途牛牛
Protagonist selects GLP-1/GIP/GCG receptor agonist peptide for obesity - BioWorld MedTech
Protagonist Hopes To Come From Behind In Obesity With Oral Triple Agonist - insights.citeline.com
Transcript : Protagonist Therapeutics, Inc.Special Call - MarketScreener
Protagonist Announces Nomination of PN-477, an Oral and Injectable GLP-1R, GIPR, and GCGR Triple Agonist Peptide Development Candidate for Obesity - The Oklahoman
Protagonist Therapeutics to Host Conference Call to Announce an - GuruFocus
Protagonist Therapeutics, Takeda Pharmaceutical Announce Positive Phase 3 Rusfertide Results for Polycythemia Vera - Yahoo Finance
Citi Rates Protagonist Therapeutics (PTGX) as Buy Protagonists Drugs Opportunity - Yahoo Finance
10 Biotech Stocks Screaming a Buy - Insider Monkey
Protagonist Therapeutics’ SWOT analysis: biotech stock poised for growth By Investing.com - Investing.com South Africa
Protagonist Therapeutics’ SWOT analysis: biotech stock poised for growth - Investing.com
BIOTECHNOLOGY VALUE FUND L P's Strategic Acquisition in Protagonist Therapeutics Inc - GuruFocus
Citigroup Initiates Coverage on Protagonist Therapeutics (PTGX) with a 'Buy' Rating | PTGX Stock News - GuruFocus
Protagonist Therapeutics (PTGX) Initiated at Buy by Citi with $7 - GuruFocus
Citigroup Initiates Protagonist Therapeutics at Buy With $72 Price Target - MarketScreener
Protagonist Therapeutics (PTGX) Initiated at Buy by Citi with $72 Target | PTGX Stock News - GuruFocus
Citi initiates Protagonist Therapeutics stock with buy rating on drug potential - Investing.com Nigeria
How To Trade (PTGX) - news.stocktradersdaily.com
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Given Consensus Rating of "Buy" by Analysts - MarketBeat
GAMMA Investing LLC Raises Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Insider Sells $570,300.00 in Stock - MarketBeat
Protagonist Therapeutics’ SWOT analysis: promising pipeline drives stock outlook By Investing.com - Investing.com Canada
Finanzdaten der Protagonist Therapeutics Inc-Aktie (PTGX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Protagonist Therapeutics Inc-Aktie (PTGX) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
MOLINA ARTURO MD | Chief Medical Officer |
Jun 09 '25 |
Option Exercise |
8.04 |
10,000 |
80,400 |
93,892 |
MOLINA ARTURO MD | Chief Medical Officer |
Jun 10 '25 |
Option Exercise |
8.04 |
10,000 |
80,400 |
93,892 |
MOLINA ARTURO MD | Chief Medical Officer |
Jun 10 '25 |
Sale |
57.03 |
10,000 |
570,300 |
83,892 |
MOLINA ARTURO MD | Chief Medical Officer |
Jun 09 '25 |
Sale |
55.51 |
10,000 |
555,100 |
83,892 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):